Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Alnylam Pharmaceuticals I...

    NASDAQ: ALNY · Real-Time Price · USD
    331.91
    2.14 (0.65%)
    At close: Jul 03, 2025, 3:39 PM
    331.91
    0.00%
    After-hours: Jul 03, 2025, 04:05 PM EDT
    0.65%
    Bid 320
    Market Cap 43.28B
    Revenue (ttm) 2.35B
    Net Income (ttm) -269.7M
    EPS (ttm) -2.11
    PE Ratio (ttm) -157.3
    Forward PE 178.17
    Analyst Buy
    Ask 334
    Volume 431,157
    Avg. Volume (20D) 1,007,063
    Open 330.00
    Previous Close 329.77
    Day's Range 327.88 - 333.70
    52-Week Range 205.87 - 333.70
    Beta 0.21

    About ALNY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ALNY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ALNY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Alnylam Pharmaceuticals Inc. is scheduled to release its earnings on Jul 31, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 months ago
    +2.6%
    Alnylam Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
    3 months ago
    +11.75%
    Alnylam Pharmaceuticals shares are trading higher after the company secured FDA approval pf sNDA for its RNAi therapeutic, AMVUTTRA ,for treatment of ATTR-CM in adults.
    news image

    3 days ago · benzinga.com

    Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

    Alnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure.

    news image

    2 weeks ago · marketwatch.com

    Alnylam Pharmaceuticals Names Garg R&D Chief

    Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.

    news image

    2 weeks ago · businesswire.com

    Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed E...

    news image

    3 weeks ago · zacks.com

    Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM

    ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

    news image

    3 weeks ago · businesswire.com

    Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted...

    news image

    1 month ago · businesswire.com

    Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman S...

    news image

    1 month ago · fool.com

    3 High-Flying Stocks That Could Soar Even More

    Many investors love the "big mo." That's short for "big momentum.

    news image

    1 month ago · businesswire.com

    AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of ...

    news image

    1 month ago · businesswire.com

    Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship ...

    news image

    2 months ago · businesswire.com

    Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Secu...

    Add to Watchlist